儿童青少年急性淋巴细胞白血病的内皮功能障碍与血栓栓塞
该研究回顾性分析55例血栓栓塞病例与165例时间匹配对照,探讨三种内皮功能障碍循环生物标志物与血栓栓塞风险的关联。在年龄、性别和风险组校正分析中,血栓调节蛋白和VEGFR-1水平升高与血栓栓塞风险增加独立相关,且关联在血栓诊断前30天以上采集的样本中仍显著。若在其他队列验证,这两个标志物或可用于识别需要预防性抗血栓治疗的患者。
要点
- 血栓调节蛋白和VEGFR-1水平升高与ALL患者血栓栓塞风险独立相关。
- 关联在血栓诊断前30天以上采集的样本中仍显著。
- 可测天冬酰胺酶活性的样本中血栓调节蛋白平均高3.2 ng/mL。
核心结论
- 血栓调节蛋白和VEGFR-1水平升高与ALL患者血栓栓塞风险增加独立相关。
研究设计与样本
- 回顾性研究,纳入55例血栓栓塞病例和165例时间匹配对照,均按NOPHO ALL2008方案治疗。
- 在内皮功能障碍生物标志物前瞻性采集的血样中检测血栓调节蛋白、syndecan-1和VEGFR-1。
主要发现
- 年龄、性别和风险组校正后,血栓调节蛋白每增加1 ng/mL,血栓栓塞风险OR为1.37(95% CI 1.20‒1.56,P < 0.0001)。
- VEGFR-1每增加100 pg/mL,血栓栓塞风险OR为1.21(95% CI 1.02‒1.21,P = 0.005)。
- 仅纳入血栓栓塞诊断前30天以上采集的样本时,上述关联仍显著。
- 可测天冬酰胺酶活性的样本中,血栓调节蛋白水平平均高3.2 ng/mL(95% CI 2.6-8.2 ng/mL,P < 0.0001)。
- 三个生物标志物编码基因内或邻近的单核苷酸变异均与血栓栓塞风险无显著关联。
临床怎么用
- 若结果在其他队列验证,血栓调节蛋白和VEGFR-1可作为预测生物标志物,识别需要预防性抗血栓治疗的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Endothelial dysfunction has not previously been investigated as a thrombogenic risk factor among patients with acute lymphoblastic leukemia (ALL), known to be at high risk of thromboembolism. We retrospectively explored the association between three circulating biomarkers of endothelial dysfunction (thrombomodulin, syndecan-1, VEGFR-1) measured in prospectively collected blood samples and risk of thromboembolism in 55 cases and 165 time-matched controls, treated according to the NOPHO ALL2008 protocol. In age-, sex-, and risk group-adjusted analysis, increasing levels of thrombomodulin and VEGFR-1 were independently associated with increased odds of developing thromboembolism (OR 1.37 per 1 ng/mL [95% CI 1.20‒1.56, P < 0.0001] and OR 1.21 per 100 pg/mL [95% CI 1.02‒1.21, P = 0.005], respectively). These associations remained significant when including only samples drawn >30 days before thromboembolic diagnosis. Thrombomodulin levels were on average 3.2 ng/mL (95% CI 2.6-8.2 ng/mL) higher in samples with measurable asparaginase activity (P < 0.0001). Among single nucleotide variants located in or neighboring coding genes for the three biomarkers, none were significantly associated with odds of thromboembolism. If results are validated in another cohort, thrombomodulin and VEGFR-1 could serve as predictive biomarkers, identifying patients in need of preemptive antithrombotic prophylaxis.
引用
- Andrés-Jensen L, Grell K, Rank CU, et al. Endothelial dysfunction and thromboembolism in children, adolescents, and young adults with acute lymphoblastic leukemia. Leukemia. 2021. PMID: 34389803. doi:10.1038/s41375-021-01383-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。